INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. following a significant drop in stock price due to halted clinical trials [1][3]. Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3]. - Following this announcement, Senti's stock price decreased by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors of Senti and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation [1].